Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections

FEMS Immunology and Medical Microbiology

Volumn 36, Issue 1-2, 2003, Pages 103-110

  Pellegrino, Rafael ^a   Galvalisi, Umberto ^a   Scavone, Paola ^a   Sosa, Vanessa ^a   Zunino, Pablo ^a  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

Author keywords

Fimbrial protein; Proteus mirabilis; Systemic immunisation; Urinary tract infection

Indexed keywords

BACTERIAL ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; PROTEIN MRPA; PROTEIN PMFA; PROTEIN UCAA; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIMBRIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEUS MIRABILIS; URINARY TRACT INFECTION;

EID: 0037447986     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(03)00103-2     Document Type: Article

References (33)

1. Stamm W.E., Martin S.M., Bennett J.V. Epidemiology of nosocomial infections due to Gram negative bacilli: aspects relevant to development and use of vaccines. J. Infect. Dis. 136:1997;S151-S160.
2. Senior B.W. The special affinity of particular types of P. mirabilis for the urinary tract. J. Med. Microbiol. 12:1978;1-8.
3. Rozalski A., Sidorcyk Z., Kotelko K. Potential virulence factors of Proteus bacilli. Microbiol. Mol. Biol. Rev. 61:1997;65-89.
4. Coker C., Poore C.A., Li X., Mobley H.L. Pathogenesis of Proteus mirabilis urinary tract infection. Microbes Infect. 2:2000;1497-1509.
5. Zunino P., Geymonat L., Allen A.G., Legnani-Fajardo C., Maskell D.J. Virulence of a Proteus mirabilis ATF isogenic mutant is not impaired in a mouse model of ascending urinary tract infection. FEMS Immunol. Med. Microbiol. 29:2000;137-144.
6. Johnson, J.R. (1996) In: Urinary Tract Infections: Molecular Pathogenesis and Clinical Management (Mobley, H.L.T. and Warren, J.W., Eds.), pp. 95-118. ASM Press, Washington, DC.
7. Hooton T.M., Shcoles D., Hughes J.P., Winter C., Roberts P.L., Stapleton A.E., Stergachis A., Stamm W.E. A prospective study of risk factors for urinary infection in young women. N. Engl. J. Med. 335:1996;468-474.
8. Langermann S., Palaszyenski S., Barnhart M., Auguste G., Pinkner J.S., Burlein J., Barren P., Koenig S., Leath S., Jones C.H., Hultgren S.J. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 276:1997;607-611.
9. O'Hanley, P. (1996) Prospects for urinary tract infection vaccines. In: Urinary Tract Infections: Molecular Pathogenesis and Clinical Management (Mobley, H.L.T. and Warren, J.W., Eds), pp. 405-425. ASM Press, Washington, DC.
10. Bullock W.O., Fernandez J.M., Short J.M. XL1-Blue: A high efficiency plasmid transforming recA Escherichia coli strain with beta-galactosidase selection. Biotechniques. 5:1987;376.
11. Studier F.W., Moffatt B.A. Use of a bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. Mol. Biol. 189:1985;113-130.
12. Rosenberg A.H., Lade B.N., Chui D.S., Dunn J.J., Studier F.W. Vectors for selective expression of cloned DNAs by T7 RNA polymerase. Gene. 56:1987;125-135.
13. Maskell D.J., Morrisey P., Dougan G. Cloning and nucleotide sequence of the aroA gene of Bordetella pertussis. J. Bacteriol. 170:1988;2467-2471.
14. Bahrani F.K., Mobley H.L.T. Proteus mirabilis MR/P fimbrial operon: Genetic organization, nucleotide sequence, and conditions for expression. Infect. Immun. 176:1994;3412-3419.
15. Zunino P., Geymonat L., Allen A.G., Preston A., Maskell D.J. New aspects of the role of MR/P fimbriae in Proteus mirabilis urinary tract infection. FEMS Immunol. Med. Microbiol. 31:2001;113-120.
16. Cook S.W., Mody N., Valle J., Hull R. Molecular cloning of Proteus mirabilis uroepithelial cell adherence (uca) genes. Infect. Immun. 63:1995;2082-2086.
17. Massad G., Mobley H.L.T. Genetic organization and complete sequence of the Proteus mirabilis pmf fimbrial operon. Gene. 150:1994;101-104.
18. Altschul S.F., Gish W., Miller W., Myers E.W., Lipman D.J. Basic local alignment search tool. J. Mol. Biol. 215:1990;403-410.
19. Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Molecular Cloning: a Laboratory Manual. Cold Spring Harbor Press, Cold Spring Harbor, NY.
20. Zunino P., Piccini C., Legnani-Fajardo C. Flagellate and non-flagellate P. mirabilis in the development of experimental urinary tract infection. Microbiol. Pathol. 16:1994;379-385.
21. Peerbooms P., Verweij A., MacLaren P. Urinary virulence of Proteus mirabilis in two experimental mouse models. Infect. Immun. 36:1982;1246-1248.
22. Berquist C., Johansson E., Lagergard T., Holmgren J., Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect. Immun. 65:1997;2676-2684.
23. Russo T.A., Stapleton A., Wenderoth S., Hooton T.M., Stamm W.E. Chromosomal restriction fragments length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. J. Infect. Dis. 172:1995;440-445.
24. Morin M.D., Hopkins W.J. Treatment of mice with staphylococcal enterotoxin B enhances resolution of an induced Escherichia coli urinary tract infection and stimulates production of proinflammatory cytokines. Infect. Immun. 66:1998;2466-2470.
25. Hedges S., Agace W., Svensson M., Sjögren A.-C., Ceska M., Svanborg C. Uroepithelial cells are part of a mucosal cytokine network. Infect. Immun. 62:1994;2315-2321.
26. De Ree J., van den Bosch J. Serological response to the P fimbriae of uropathogenic Escherichia coli in pyelonephritis. Infect. Immun. 55:1987;2204-2207.
27. Hopkins W.J., Uehling D.T. Resolution time of Escherichia coli cystitis is correlated with levels of preinfection antibody to the infecting Escherichia coli strain. Urology. 45:1995;42-46.
28. Moayeri N., Collins C.M., O'Hanley P. Efficacy of a Proteus mirabilis outer membrane protein vaccine in preventing experimental pyelonephritis in a BALB-c mouse model. Infect. Immun. 59:1991;3778-3786.
29. Langermann S., Palaszyenski S., Barnhart M., Auguste G., Pinkner J.S., Burlein J., Barren P., Koenig S., Leath S., Jones C.H., Hultgren S.J. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science. 276:1997;607-611.
30. Agace, W., Connell, H. and Svanborg, C. (1996) Host resistance to urinary tract infection. In: Urinary Tract Infections: Molecular Pathogenesis and Clinical Management (Mobley, H.L.T. and Warren, J.W., Eds), pp. 221-243. ASM Press, Washington, DC.
31. Langermann S., Mollby R., Burlein J.E., Palaszynski S.R., Auguste C.G., De Fusco A., Strouse R., Schenerman M.A., Hultgren S.J., Pinkner J.S., Winberg J., Guldevall L., Soderhall M., Ishikawa K., Normark S., Koenig S. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J. Infect. Dis. 181:2000;774-778.
32. Nicolle L.E. Resistant pathogens in urinary tract infections. J. Am. Geriatr. Soc. 50:2002;S230-S235.
33. Mutnik A.H., Turner P.J., Jones R.N. Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility test information collection. J. Chemother. 14:2002;253-258.